
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 earnings estimates for Armata Pharmaceuticals in a research report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $2.63 per share for the year, up from their prior estimate of $0.50. HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is $2.63 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2026 earnings at ($0.51) EPS and FY2027 earnings at ($1.92) EPS.
Armata Pharmaceuticals Price Performance
Shares of ARMP stock opened at $3.17 on Tuesday. Armata Pharmaceuticals has a 1-year low of $2.40 and a 1-year high of $14.98. The firm has a fifty day moving average of $3.63 and a two-hundred day moving average of $6.79.
Institutional Investors Weigh In On Armata Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. bought a new stake in Armata Pharmaceuticals in the third quarter valued at about $92,000. Empowered Funds LLC acquired a new stake in Armata Pharmaceuticals during the third quarter valued at approximately $149,000. Nisa Investment Advisors LLC bought a new position in Armata Pharmaceuticals during the 3rd quarter worth approximately $50,000. Bank of America Corp DE bought a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $73,000. Finally, Madison Asset Management LLC bought a new position in Armata Pharmaceuticals during the 2nd quarter worth approximately $13,654,000. Institutional investors and hedge funds own 3.57% of the company’s stock.
About Armata Pharmaceuticals
Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.
Featured Articles
- Five stocks we like better than Armata Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
